Myeloma genetics and genomics: practice implications and future directions

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a complex plasma cell disorder.
• Accurate diagnosis and monitoring depend on established biomarkers like electrophoresis and free light chains.
• Current prognostic models, including Durie-Salmon and ISS, assess disease burden.

Purpose of the Study:

• To review current diagnostic and prognostic tools for multiple myeloma.
• To highlight the role of advanced biomarker and genetic testing.
• To discuss the future direction of MM therapy towards minimal residual disease (MRD).

Main Methods:

• Review of established diagnostic biomarkers (serum/urine protein electrophoresis, serum free light chains).
• Evaluation of prognostic staging systems (Durie-Salmon, ISS).
• Discussion of advanced techniques: cytogenetics, FISH, gene expression profiling.

Main Results:

• Biomarkers and staging systems are crucial for MM diagnosis and prognosis.
• Advanced genetic testing aids in assessing disease aggressiveness and personalizing treatment.
• Minimal residual disease (MRD) detection is a key future therapeutic goal.

Conclusions:

• Integrating biomarkers and genomic data is essential for optimizing MM patient care.
• MRD testing promises improved assessment of treatment response and survival outcomes.
• Further research is needed to develop novel strategies for relapsed/refractory MM.